Runda Medical issued a performance forecast on the evening of July 19, and it is expected that the net profit attributable to shareholders of listed companies will be between 195 million yuan and 215 million yuan in the first half of 2021, an increase of 83.78 million yuan to 104 million yuan compared with the same period of the previous year. , An increase of 75.33% year-on-year to 93.31%.

The main reason for the pre-increased performance in this period is: in the first half of 2020, affected by the new crown epidemic, the demand for terminal hospitals has experienced a substantial decline in stages, which has a greater impact on the company's main business. During the reporting period, the hospital resumed normal medical treatment activities, and the company's various businesses were steadily carried out. At the same time, the company is actively expanding the market, the number of customers and income of comprehensive service business have gradually increased, and the synergy of the company's self-produced products has gradually been highlighted, comprehensively promoting the improvement of the company's profitability, and the company's operating performance has achieved steady growth.

About Runda Medical:

Shanghai Runda Medical Technology Co., Ltd. (Runda Medical, A-share code 603108) was established in 1999 and is headquartered in Shanghai, China. It is a comprehensive medical laboratory service provider based in East China and covering the whole country. Its main business is through its own The comprehensive service system provides comprehensive services of in vitro diagnostic products and professional technical support to various medical laboratories.

Runda Medical has more than 40 wholly-owned or holding subsidiaries across the country and overseas, and its business covers most of the provinces, cities and regions in the country, and the products it provides cover the in-vitro diagnostics industry (IVD, In-Vitro Diagnostics) Mainly subdivided areas, Runda Medical has now developed into one of the leading companies in the domestic IVD industry for product circulation and comprehensive services.